PMID: 19836806
Question: Should prostate specific antigen be adjusted for body mass index?
Correct Answer: no

======================= Launch the MCC process =======================
PMID: 19836806
Question: Should prostate specific antigen be adjusted for body mass index?

----- GPT's initial response -----
GPT is reasoning the answer...


**1. Question Analysis**
- **Core Content:** The research question investigates whether prostate specific antigen (PSA) levels should be adjusted based on an individual's body mass index (BMI).
- **Key Information to Look For:** The relationship between BMI and PSA levels, statistical significance of this relationship, and the authors' conclusions regarding the necessity of adjusting PSA for BMI.

**2. Evidence Evaluation**
- **Research Results:** The study found that BMI was not significantly associated with PSA levels after adjusting for age (p = 0.06). A 10-point increase in BMI was linked to a minimal PSA difference of -0.03 ng/ml, with a wide confidence interval (-0.40 to 0.49), indicating no substantial or consistent effect.
- **Strength and Reliability:** The study included a sizable population (994 men without prostate cancer) and utilized mixed effects models, enhancing the reliability of the findings. The consistency of results across various models and adjustments further strengthens the evidence.
- **Relevance:** The evidence directly addresses the question by evaluating the necessity of adjusting PSA levels for BMI, providing clear data and analysis relevant to the decision.

**3. Conclusion**
Based on the evidence, there is no significant or meaningful association between BMI and PSA levels that would warrant adjusting PSA for BMI in clinical practice.

**4. Final Answer:**
**My final choice is: "no"**
GPT selected: no

----- Qwen's initial response -----
Qwen is reasoning the answer...


**1. Question Analysis**  
The question asks whether prostate-specific antigen (PSA) levels should be adjusted for body mass index (BMI). The key information to assess is whether BMI significantly influences PSA levels in a clinically meaningful way, as suggested by the study's findings.  

**2. Evidence Evaluation**  
- The study found no significant association between BMI and PSA after adjusting for age (p = 0.06).  
- A 10-point increase in BMI was linked to a PSA difference of -0.03 ng/ml (95% CI: -0.40 to 0.49), which is a negligible effect size.  
- Similar results were observed when substituting BMI with percent body fat, adjusting for prostate volume, or analyzing longitudinal weight changes.  
- The abstract concludes that the inverse relationship between obesity and PSA exists but is too small to warrant adjusting PSA for BMI.  

The evidence is strong and directly addresses the question. The study's large sample size (994 men, 4,937 observations) and longitudinal design enhance reliability. The confidence interval includes zero, indicating no meaningful association.  

**3. Conclusion**  
The study demonstrates that while there is a weak inverse relationship between BMI and PSA, the effect size is clinically insignificant. Adjusting PSA for BMI would not meaningfully improve diagnostic accuracy.  

**4. Final Answer:**  
**My final choice is: "no"**
Qwen selected: no

----- Deepseek's initial response -----
DeepSeek is reasoning the answer...

**1. Question Analysis**  
The question asks whether prostate-specific antigen (PSA) should be adjusted for body mass index (BMI) due to concerns that obesity may lower PSA via hemodilution. The key focus is determining if the study provides evidence supporting such an adjustment.

**2. Evidence Evaluation**  
- The study analyzed 994 men without prostate cancer (4,937 observations) and found **no significant association** between BMI and PSA after adjusting for age (p = 0.06).  
- A 10-point BMI increase corresponded to a clinically negligible PSA difference of **-0.03 ng/ml** (95% CI: -0.40â€“0.49), with the confidence interval spanning zero, indicating no meaningful effect.  
- Results remained consistent across sensitivity analyses: including men with prostate cancer, substituting BMI with percent body fat, adjusting for prostate volume, and evaluating longitudinal weight changes.  
- The authors conclude that the inverse relationship between obesity and PSA is statistically and clinically insignificant, making BMI adjustment unwarranted.  

**3. Conclusion**  
The study provides robust evidence against adjusting PSA for BMI. The lack of statistical significance, minimal effect size, and consistent null findings across multiple analyses strongly support rejecting BMI adjustment for PSA.  

**4. Final Answer**  
**My final choice is: "no"**
DeepSeek selected: no

Initial consensus: All models selected no